Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q4G163
UPID:
FBX43_HUMAN
Alternative names:
Endogenous meiotic inhibitor 2
Alternative UPACC:
Q4G163
Background:
F-box only protein 43, also known as Endogenous meiotic inhibitor 2, plays a crucial role in reproductive biology. It is essential for maintaining oocytes at the second meiotic metaphase until fertilization, by inhibiting the APC/C ubiquitin ligase. This protein is involved in the ubiquitination and degradation of phosphorylated proteins, including CCNB1 and CDK1, which are key in gametogenesis.
Therapeutic significance:
F-box only protein 43 is linked to diseases such as Oocyte/zygote/embryo maturation arrest 12 and Spermatogenic failure 64, both of which affect fertility. Understanding the role of F-box only protein 43 could open doors to potential therapeutic strategies for these reproductive disorders.